Immunoglobulins comprising predominantly a Man5GlcNac2 glycoform

Details for Australian Patent Application No. 2005269713 (hide)

Owner GlycoFi, Inc.

Inventors Wildt, Stefan; Gerngross, Tillman U.; Li, Huijuan

Agent Spruson & Ferguson

Pub. Number AU-A-2005269713

PCT Pub. Number WO2006/014726

Priority 60/589,926 21.07.04 US; 60/589,979 21.07.04 US

Filing date 19 July 2005

Wipo publication date 9 February 2006

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 16/22 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12N 15/10 (2006.01) Mutation or genetic engineering - Processes for the isolation, preparation or purification of DNA or RNA

Event Publications

15 February 2007 PCT application entered the National Phase

  PCT publication WO2006/014726 Priority application(s): WO2006/014726

18 June 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005269716-Inhibitors of angiopoietin-like 4 protein, combinations, and their use

2005269712-Immunoglobulins comprising predominantly a GlcNAcMan5GlcNAc2 glycoform